Coloplast H1 2025/26 slides: 6% organic growth offset by currency headwinds

Coloplast delivered 6% organic growth in Q2 and 33% higher adjusted free cash flow to DKK 2,816 million, but reported first-half revenue rose just 1% to DKK 14,127 million because of 4 percentage points of currency drag and Skin Care divestment. EBIT margin compressed to 26% from 27.2%, prompting a cut in full-year guidance to 5-6% organic growth and about 3% reported revenue growth in DKK. The stock fell 0.25% on the update, reflecting caution around FX headwinds despite solid underlying demand across key care segments.

Analysis

The first-order takeaway is not that the business is slowing; it’s that FX is masking operating leverage while the market is pricing the headline number as if demand were weakening. That creates a setup where the next catalyst is likely denominator-driven: if the dollar stabilizes or weakens, reported growth and margins can rebound quickly without any change in unit economics. The more interesting second-order effect is that the new manufacturing footprint and working-capital discipline are starting to offset part of the margin drag, which means the earnings base is becoming less brittle than the current multiple implies.

The real vulnerability is segment mix, not top-line momentum. Kerecis and the China dressings issue suggest the portfolio still has pockets where regulatory friction and geographic noise can overwhelm otherwise healthy core categories, so consensus may be underestimating how long it takes to normalize these smaller drags. That said, strong cash conversion and stable ROIC argue this is not a balance-sheet story; it is a perception story, and those tend to mean-revert faster than operating misses when the market’s concern is cyclical rather than structural.

For peers, the pressure is more subtle: if Coloplast can preserve volume growth while reinvesting through supply chain localization, it raises the bar for medtech companies that depend more heavily on imported input costs or less diversified distribution. Conversely, suppliers and contract manufacturers in lower-cost regions could benefit as firms like this continue to de-risk FX and tariff exposure through multi-site capacity. On the healthcare complex, the read-through to JNJ is mildly positive only insofar as management execution and portfolio resilience matter more than near-term reported growth in a volatile currency tape.

Key Decisions for Investors

• Add to COLOb/COLOB on weakness over the next 2-4 weeks if FX does not worsen materially; risk/reward is attractive because reported growth can re-accelerate mechanically even at flat underlying demand.
• Pair trade: long COLOB vs short a more FX-sensitive medtech peer with weaker organic growth visibility over the next 1-3 months; the trade benefits from mean reversion in reported margins and cash-flow quality.
• Use call spreads rather than outright longs if adding exposure: 3-6 month COLOB upside optionality is cheap when sentiment is anchored to reported numbers, with limited downside if currency headwinds persist.
• For JNJ, maintain a small relative-value long only; the read-through is execution-positive but not strong enough for directional conviction. Best expressed as a portfolio hedge against broader healthcare weakness, not a standalone catalyst trade.
• Watch for any stabilization in USD/DKK and GBP/DKK over the next quarter; that is the highest-probability catalyst to close the gap between organic growth and reported revenue, which could drive multiple expansion.